Ventyx biosciences announces $100 million private placement of common stock

San diego, march 07, 2024 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share in a private placement to certain qualified institutional buyers and institutional accredited investors. gross proceeds of the private placement are expected to be approximately $100 million, before deducting placement agent fees and other expenses. the private placement is expected to close on march 11, 2024, subject to the satisfaction of customary closing conditions.
VTYX Ratings Summary
VTYX Quant Ranking